Ann: Starpharma completes US New Drug Application for VivaGel BV, page-21

Interesting point Joel. Maybe the condom market may actually come to something. No pun intended.

I’ve been a sceptic but it could end up proving to be a nice side earner for SPL with little effort required once up and running and some market penetration achieved. Again no pun intended.

I Wonder what the latest is on the China condom negotiations. They appear to have gone a bit soft on this for some time. Ok pun intended.

More importantly, DEP dox trials seem to be enrolling patients. But I wish they would use specific numbers instead of terms like several or numerous, this is deliberately vague. This trial is so critical for SPL.